...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
【24h】

A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.

机译：一项随机分配的双盲交叉研究，研究了普拉克索和培高利特的相对抗帕金森氏震颤作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study examined the relative anti-Parkinson's disease (PD) tremor potencies of pergolide and pramipexole in people with PD, using a 3-month double-blind cross-over design. Patients were randomly assigned to receive either pergolide and then pramipexole (n = 9) or vice versa (n = 8). The dose of the respective dopamine agonist was increased according to a titration schedule up to a maximum 1.5 mg t.d.s., with cross-over at 10 weeks. Assessments were performed at baseline, 4, 8 and 12 weeks. The primary outcome measures were the differences in the clinical (rest and postural) tremor scores on pergolide versus pramipexole. Seventeen PD patients (11 females and six males) with a mean age 68.4 years (range: 55-84 years) and a mean disease duration of 3.9 years (range: 2 months to 13 years) participated in the study. Twelve of the patients were taking other anti-parkinsonian medications. Two patients dropped out of the study whilst on pergolide. Fifteen of 16 patients were able to cross-over from one dopamine agonist to the other, without major retitration. There were no significant differences between the effects of the two drugs on the primary outcome measures, suggesting that the anti-PD tremor efficacies of dopaminergic medications are not dependent on differential affinities for dopamine receptor types.
机译：这项研究使用3个月的双盲交叉设计检查了PD患者中培高利特和普拉克索的相对抗帕金森氏病（PD）震颤效能。患者被随机分配接受培高利特然后接受普拉克索（n = 9）治疗，反之亦然（n = 8）。多巴胺激动剂的各自剂量根据滴定时间表增加至最大1.5 mg t.d.s.，并在10周时交叉使用。在基线，第4、8和12周进行评估。主要的结局指标是培高利特与普拉克索的临床（静息和姿势）震颤评分的差异。参加研究的17名PD患者（11名女性和6名男性）平均年龄为68.4岁（范围：55-84岁），平均病程为3.9年（范围：2个月至13岁）。十二名患者正在服用其他抗帕金森病药物。两名患者在服用培高利特时退出研究。 16名患者中有15名能够从一种多巴胺受体激动剂过渡到另一种，而无需进行大的撤药。两种药物对主要结局指标的作用之间无显着差异，这表明多巴胺能药物的抗PD震颤功效不依赖于多巴胺受体类型的不同亲和力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号